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ABSTRACT  
Objective: Co-crystal is defined as a crystalline complex of two or more neutral molecules bound together primarily by hydrogen bonding or other 
non-covalent interactions. The pharmaceutical co-crystal involves crystal lattice arrangement between an Active Pharmaceutical Ingredient (API) 
with another pharmaceutically acceptable molecule. Co-crystals of API are preferred since they depict improved solubility, dissolution, stability, 
compressibility in comparison with API. Ibuprofen lysine (IL), frequently used analgesic and the anti-inflammatory drug has poor aqueous solubility 
and compressibility. This work shows the feasibility and optimal conditions for the preparation of co-crystals of ibuprofen lysine using 
Polyvinylpyrrolidone K25 (PK 25) and Polyvinylpyrrolidone K30 (PK 30) as co-formers.  
Methods: In this study, we prepared and studied the solubility, drug content, flow properties, physical stability of novel co-crystal, consisting of IL 
and PK 25/PK 30. The co-crystal IL: PK 30 (at a molar ratio of 0.29:0.5) and IL: PK 25 (at a molar ratio of 0.58:1) were characterized by X-ray 
analysis, infrared spectroscopy and thermal analysis. Furthermore, the tablet formulations of the co-crystals were subjected to in vitro dissolution 
and in vivo analgesic activity, with the goal of comparing the co-crystals with IL and the marketed tablet of ibuprofen (Brufen®) respectively.  
Results: The IL: PK co-crystals demonstrated superior solubility and the dissolution properties over IL. The compression properties of the co-
crystals were similar to IL. The co-crystals exhibited higher analgesic activity than the marketed tablet.  
Conclusion: The results indicated the use of PK 25 and PK 30 as safe and promising co-crystal formers. 
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INTRODUCTION  
Ibuprofen is BCS class II drug having high permeability and low 
solubility. (Dose is 600 mg, dose no is 164.38) It is remembered for 
the WHO Model List of Essential Medicines of the most significant 
drugs required in a fundamental wellbeing framework [1]. Ibuprofen 
(pKa esteem 4.91) has a poor and exceptionally pH-subordinate 
solvency [2]. Ibuprofen dissolves readily above pH 6.5 and is quickly 
absorbed from the small intestine in comparison with the stomach. 
The blood level reaches to a maximum of 1.5 to 2 h after ingestion. It 
indicates delayed or incomplete absorption and is attributed to the 
pH conditions of the small intestine [1]. Designing of ibuprofen 
formulation is challenging since it has pH-dependent solubility and 
permeability [3]. The aqueous solubility of ibuprofen salts is higher 
than that of the drug substance. The variation in bioavailability of 
ibuprofen is resolved by using ibuprofen salts, in particular, 
ibuprofen lysinate, ibuprofen arginate, ibuprofen sodium [1].  
Crystal engineering is based upon complex formation between the 
molecules through supramolecular synthons leading to co-crystals, 
formation [4]. Zaworotko has characterized a co-crystal as a multi-
component crystal, formed between two solids, in which one 
component is molecular and structures a supramolecular synthon 
with the other component. This incorporates the atomic adducts of 
particles. [5, 6]. Crystal engineering is based on non-covalent 
interactions between atoms/molecules and is useful in designing 
and synthesis of solid-state structures such as salts or polymorphs. 
Co-crystallization is an ongoing methodology, utilized in 
pharmaceutical sciences, for designing the APIs having attractive 
physical and substance properties [7]. The pharmaceutical industry 
is in search of novel robust, reliable and safe supramolecular 
synthon. 
Literature search reveals the co-crystals of ibuprofen with 
nicotinamide [8], urea, succinic acid, salicylic acid, 3-and 4-
aminobenzoic acid, cinnamic acid, citric acid, oxalic acid, benzoic 
acid [3]. Significantly less research has been done on the synthesis of 
co-crystals of salts of ibuprofen.  
Polyvinylpyrrolidone is a water-soluble tertiary amide polymer of 
(N-vinyl-2-pyrrolidone) and is reported as a proton acceptor [9]. 
Polyvinylpyrrolidone is used as a carrier (in solid dispersion), 
dispersing agent, suspending agent, film former (in eye drops), 
binder, diluent, coating agent (in tablets), blood volume expander. 
However, it has received little attention as the co-former in the 
formation of co-crystals [10-11]. 
The aim of the study was to prepare the co-crystals of salt of Active 
Pharmaceutical Ingredient (API) with polymer as the co-former and 
to evaluate the solubility and the compressibility of the co-crystals. 
In this study, the salt ibuprofen lysine (IL), was used as the host 
molecule with the co-crystal formers namely, Polyvinylpyrrolidone 
K25 and Polyvinylpyrrolidone K30 (PK 25 and PK 30) possessing a 
pyrrolidine ring and an amino (NH2) group.  
MATERIALS AND METHODS 
Materials 
Ibuprofen lysine IP was generously gifted by Mylan Laboratories, 
Malegaon, Sinnar, Maharashtra. Povidone (Polyvivylpyrrolidone) 
K25 USP and Povidone K30 USP were gifted by Getz Pharma 
Research Pvt Ltd, Addl Ambernath, Thane. Brufen® tablets (Abott 
India Ltd, Verna, Goa) were procured from the local market. Talc IP, 
magnesium stearate IP, microcrystalline cellulose IP was purchased 
from New Neeta Chemicals, Chinchwad, Pune. Absolute ethanol AR 
was used as received from Rathod Suppliers, Pune. 
Screening of co-crystals by the solvent evaporation method  
Accurately weighed ibuprofen lysine was dissolved in ethanol (5 
ml). Polyvinylpyrrolidone K-25/polyvinylpyrrolidone K-30 was 
dissolved in 5 ml of ethanol. (table 1) The coformer solution was 
added to the ibuprofen lysine solution gradually with continuous 
stirring at 2000 rpm for 20 min at 35 °C. The stirring was 
continued till complete dissolution. The container was left 
uncapped for gradual evaporation of the solvent at 35 °C for 1 w. 
White-colored co-crystals were obtained and triturated gently in 
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the pestle mortar to a fine powder before analyses. Each 
formulation was prepared in three sets. 
Screening of co-crystals by liquid assisted grinding method  
Accurately weighed ibuprofen lysine was mixed with polyvinyl-
pyrrolidone K-25/polyvinylpyrrolidone K-30 in the pestle mortar in 
the absence of any solvent for 20 min. (table 1) initial mixing was 
followed by the dropwise addition of ethanol (5 ml) and continuous 
trituration for 20 min. The container was left uncapped for gradual 
evaporation of the solvent at 35 °C for 1 w.  White-colored co-crystals 
were obtained and triturated gently in the pestle mortar to a fine 
powder before analyses. Each formulation was prepared in three sets. 
 
Table 1: Screening of co-crystals of ibuprofen lysine 
S. 
No. 










1 IL+K-25 1.16: 2 0.8241 0.0485 A1 B1 
2 IL+K-30 1.16: 2 0.8241 0.0598 A2 B2 
3 IL+K-25 1.16: 1 0.8241 0.0242 A3 B3 
4 IL+K-30 1.16: 1 0.8241 0.0299 A4 B4 
5 IL+K-25 0.58: 1 0.4120 0.0242 A5 B5 
6 IL+K-30 0.58: 1 0.4120 0.0299 A6 B6 
7 IL+K-25 0.29: 0.5 0.2060 0.0121 A7 B7 
8 IL+K-30 0.29: 0.5 0.2060 0.0149 A8 B8 
Where, IL–Ibuprofen lysine; K-25-polyvivylpyrrolidone K-25; K-30-polyvivylpyrrolidone K-30  
 
Evaluation of co-crystals of ibuprofen lysine  
The % yield, the solubility and the drug content of the co-crystals 
were determined. 
The % yield of the co-crystal formulations was determined as 
follows. 
% yield =
weight of co − crystal formulation
weight of drug + co − former
x 100 
For determination of solubility, excess of ibuprofen lysine/co-
crystals was added to distilled water (10 ml). The drug content was 
evaluated by adding co-crystal formulation (equivalent to 30 mg of 
drug substance) to ethanol (10 ml). The suspension was agitated on 
a magnetic stirrer at 100±10 rpm for 24 h at 37±0.5 °C and filtered 
through Whatman filter paper no. 41. The absorbance was measured 
at 221 nm with UV Spectrophotometer (Varian Cary 100 Scan). The 
UV spectrophotometric method was developed and validated in our 
laboratory. Results are not disclosed. Drug content was calculated as 
follows.  




The angle of repose, bulk and tapped density, Hausner’s ratio, 
Compressibility Index of the co-crystals A5 and B8 were determined 
and compared with ibuprofen lysine. The structure of the co-crystals 
A5 and B8 were identified by Fourier Transformer Infrared 
spectroscopy, Differential Scanning Calorimetry and Powder X-Ray 
Diffractometry. The surface characteristics of IL, PK 25, PK 30, co-
crystals A5 and B8 were studied with Motic microscope (Motic BA 
210). The samples (10 mg) were mounted on a glass slide and 
observed under the microscope.  
Stability study  
The co-crystals A5 and B8 were wrapped in double layers of 
aluminum foil and were stored at 40±2 °C and 75±5% relative 
humidity in a stability chamber (Thermo Labs) [12]. The physical 
appearance, the drug content and the solubility of the co-crystals 
were examined at pre-determined time intervals for 3 mo. 
Preparation of tablet formulations of co-crystals of ibuprofen 
lysine  
The tablet formulations consisting of ibuprofen lysine: polyvinyl-
pyrrolidone K25/K30 co-crystals or ibuprofen lysine alone were 
prepared. Direct compression was employed for preparing three 
tablet formulations, namely, ibuprofen lysine (tablet T1), ibuprofen 
lysine: PK 25 co-crystal A5 (tablet T2) and ibuprofen lysine: PK 30 
co-crystal B8 (tablet T3). Following excipients were incorporated: 
Avicel pH 102 (microcrystalline cellulose) (112.0 mg), magnesium 
stearate (1.25 mg) and talc (8.75 mg) per tablet with co-crystal A5 
(300 mg equivalent to 228 mg of ibuprofen lysine) and co-crystal B8 
(228 mg equivalent to 228 mg of ibuprofen lysine), respectively. A 
tablet press instrument (Mini Press-ɪɪ ‘D’ Rimek) was used for this 
purpose (table 2). 
 
Table 2: Formulation of tablets of co-crystals of ibuprofen lysine 






1 Ibuprofen lysine Drug substance 228 - - 
2 Co-crystal formulation A5 Drug substance - 300 - 
3 Co-crystal formulation B8 Drug substance - - 228 
4 Talc Glidant 8.75 8.75 8.75 
5 Microcrystalline cellulose Binder and Diluent 112 40 112 
6 Magnesium stearate Lubricant/anti-adherent  1.25 1.25 1.25 
 
Evaluation of tablet formulations of co-crystals of ibuprofen lysine  
The appearance, dimensions [13], weight variation [13], hardness 
[14], friability [14], disintegration time [13] of tablets T1, T2, T3 
were recorded.  
In vitro dissolution 
In vitro dissolution of three tablets, containing co-crystal A5 or co-crystal 
B8 or ibuprofen lysine was performed in paddle-type USP Dissolution 
Test Apparatus (Electro Lab, TDL–08L) at 37±0.5 °C and 50 rpm. The 
dissolution medium was distilled water (900 ml). The samples were 
collected at 0, 10, 15, 20, 30, 45 and 60 min. An equal volume of fresh 
dissolution medium was replaced to maintain the volume of the 
dissolution medium. The absorbance of the withdrawn samples was 
measured at 221 nm and the drug release was determined. 
In vivo study of tablet formulations of co-crystals of ibuprofen 
lysine  
The analgesic activity of the tablet formulations of the co-crystals was 
determined by the hot plate method. Mature albino Swiss mice (5–
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30 g) of both sexes were housed under standard room temperature 
and relative humidity (70–80%). The animals were fed with standard 
commercial diet and water ad libitum. The animals were fasted for 
12 h prior to the experiment with water given ad libitum and weighed. 
All procedures were reviewed and approved by the Ethics Committee 
of (941/Po/c/06/CPCSEA; 30/06/2009). The mice were randomly 
assigned to five groups of six animals each. The first, second and third 
groups received T2, T3 and T1 tablets, respectively. The tablets were 
added to purified water, filtered and the samples (equivalent to a dose 
of 6 mg of ibuprofen/kg) were administered orally to the animals 
using an oral gavage needle. The fourth and the fifth groups served as 
positive control and negative control receiving Brufen® tablet 
equivalent to a dose of 6 mg of ibuprofen/kg) and normal saline 
(10 ml/kg). All treatments were administered orally. 
The animal was placed on a hot plate (temperature 55 °C). The 
latency period or reaction time (s) was determined as the time taken 
by the animal to react to the thermal pain by jumping or licking its 
paws. The reaction time was recorded before (at 0 min) and at 15, 
30, 45, 60 and 120 min after the administration of the tablets. The 
maximum reaction time was fixed at 15 s to prevent any injury to the 
paw tissues. If the reaction time exceeded 15 s, it was considered as 
maximum analgesia. The index of analgesia or % increase in reaction 
time was determined at each time interval. Data were presented as 
mean±standard error mean (SEM).  
RESULTS AND DISCUSSION 
Screening of co-crystals of ibuprofen lysine  
The co-formers, namely, 4-hydroxybenzoic acid [3], nicotinamide 
[18, 19] and 2-aminopyrimidine [20] were used for screening the co-
crystals of ibuprofen. In the reported crystal structures of ibuprofen, 
the molecules are linked through hydrogen-bonded supramolecular 
synthons such as acid-amide, amide dimer, acid-aromatic nitrogen, 
NH2 dimer [21] and acid dimer. Polyvinylpyrrolidone derivatives are 
used as a disintegrant, tablet binder, dissolution enhancer and 
suspending agent. However, co-crystals of APIs with 
Polyvinylpyrrolidone are not reported. We have hypothesized that 
the soluble Polyvinylpyrrolidone and API might form 
heterosynthons, which might induce co-crystallization.  
Fig. 1, drawn with Chem Draw software, shows the proposed 
hydrogen bonding between the guest and the host compounds. The 
pKa of ethanol and water is 15.9 and 15.7, respectively. Ethanol 
depicts the loss of proton from hydroxyl group [22]. Hence we 
hypothesize that ibuprofen lysine undergoes dissociation in 
ethanolic solution and forms ibuprofen and lysine. Ibuprofen 
donates 1 hydrogen and accepts 2 hydrogen. The hydrogen donor 
count and the hydrogen acceptor count of PK is 0 and 1, respectively. 
The-H from carboxylic acid functional group (-COOH) of ibuprofen 
has a potential of forming hydrogen bond with the carbonyl group (-
C=O) of PK-25 and PK-30. Ibuprofen acts as the proton donor, 
whereas PK acts as the proton acceptor. We propose that ibuprofen 
is linked with PK through hydrogen-bonded supramolecular 
synthons, namely, acid-carbonyl (an interaction between the 
carbonyl group (-C=O) of PK and the hydrogen (-H) of the carboxylic 
acid functional group of ibuprofen). 
Crystallization strategy and conditions for screening are commonly 
founded on one of two techniques. In system 1, solvents or 
dissolvable blends of solutions, with comparable solubility for 
reactants, are chosen and stoichiometric concentrations of reactants 
are utilized. In methodology 2, solvents or dissolvable blends of 
solvents, depicting different solubility for reactants, are chosen, and 
nonstoichiometric reactant arrangement is utilized [23]. In the 
present work, system 2 was chosen. The primary concern, in the 
selection of the solvent, was the solvent’s ability to create adequate 
super saturation for the co-crystal nucleation while evading 
supersaturation for the reactants. Crystallization by evaporation of 



























Hydrogen Bond  
Fig. 1: Formation of hydrogen bond in co-crystal 
 
The solid forms were set up by two strategies Liquid Assisted 
grinding (LAG) and solvent evaporation (SE). The co-crystal 
components are dissolved in a solvent and the solvent is evaporated 
gradually in solvent evaporation. However, on a modern scale, SE is 
less preferred since it requires more time for evaporation and leads 
to environmental pollution. A "green" approach is to add a solvent to 
the mixture and to grind the components together in the presence of 
the solvent (LAG). LAG experiments require less solvent, less time 
consuming, and may produce the resultant co-crystal and its 
polymorphs [8]. Two screening methods led to the discovery of 
sixteen solid forms containing ibuprofen lysine. Sixteen co-crystals 
were prepared on a scale adequate for determination of solubility, 
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drug content and flow properties. The % yield, solubility, drug 
content and flow properties of the solid forms were compared and 
the hits were decided.  
Evaluation of co-crystals of ibuprofen lysine  
Percentage (%) yield  
For all the co-crystals, the collected powders were white and fairly 
free-flowing. The percentage yield of co-crystals obtained by LAG 
was higher than by SE. (table 2 and 3) the lower yield in case of SE 
was attributed to the process loss.  
Drug content and solubility 
The solubility of ibuprofen lysine in distilled water was 5.419 
µg/ml. Both the co-formers and the crystallization techniques 
improved the aqueous solubility of ibuprofen lysine. (table 3 and 
4) The % drug content and solubility of co-crystals, consisting of 
PK-30 as the co-former and prepared by SE, were better than 
those of the co-crystals consisting of PK-25 and prepared by 
LAG. The co-crystal B8 demonstrated higher drug dissolution 
than the co-crystal A5. 
  
Table 3: Characterization of co-crystals prepared by LAG method 
S. No. Formulation code Yield (%) Drug content (%) Solubility (µg/ml) 
1 A1 84.04±13.88 46.31±14.95 41.35±7.79 
2 A2 78.09±13.89 50.89±11.49 43.69±10.58 
3 A3 83.36±12.61 55.11±12.98 43.04±15.49 
4 A4 82.80±13.39 49.95±9.67 48.64±12.94 
5 A5 91.33±5.99 44.40±0.9205 42.43±12.46 
6 A6 68.90±11.84 65.54±8.97 34.96±8.37 
7 A7 65.06±35.57 79.69±20.37 28.14±2.98 
8 A8 68.39±30.90 76.26 ±13.07 30.54 ±10.83 
 Each observation is an average of three experiments (n=3)±SD 
 
Table 4: Characterization of co-crystals prepared by SE method 
S. No. Formulation code Yield (%)  Drug content (%) Solubility (µg/ml) 
1 B1 64.81±12.42 57.85±7.79 49.73±5.43 
2 B2 63.61±18.48 49.33±3.22 50.55±16.91 
3 B3 73.55±11.88 60.31±2.78 38.99±7.25 
4 B4 78.80±18.76 49.38±5.21 40.73±6.17 
5 B5 61.76±17.31 60.92±16.03 32.7±8.82 
6 B6 66.07±12.36 54.87±5.35 43.21±7.09 
7 B7 50.48±15.88 70.93±7.33 43.84±12.33 
8 B8 72.92±4.84 87.08±19.26 53.52±4.39 
 Each observation is an average of three experiments (n=3)±SD 
 
Flow properties  
The co-crystals, A5 and B8 revealed good flow properties. However, 
the compression properties of co-crystals were not improved. The 
compression properties of B8 were slightly improved than ibuprofen 
lysine (table 5). 
Stability study  
The stability of the co-crystals A5 and B8 includes determination of 
the solubility and the drug content of the co-crystals samples at 
different time intervals and comparison with the previous results. 
The results confirmed the stability of A5 and B8 for 3 mo (table 6). 
Any significant change in the physical appearance of the co-crystals 
was not observed. 
FTIR spectroscopy  
Fig. 2, 3 and 4 show the IR spectra of ibuprofen lysine, the co-
crystals A5 and B8, respectively. The IR spectra of the polymers, 
namely, PK 25 and PK 30 are not shown. A listing of the most 
characteristic IR bands of the co-crystals examined herein is given in 
table 7 and 8, together with the data for ibuprofen lysine and the 
corresponding co-crystal formers. 
 
Table 5: Flow properties of co-crystals 
S. No. Ingredient  Angle of repose ( °) Tapped density Bulk density Carr’s index (%) Hausner’s ratio 
1 Ibuprofen lysine 31.21 0.72 0.350 51.38 2.05 
2 Co-crystals A5 26.13 0.73 0.336 53.97 2.17 
3 Co-crystals B8 26.28 0.71 0.368 48.16 1.93 
 
Table 6: Stability study of co-crystals 
Days  Co-crystal A5 Co-crystal B8  
Drug content (%) Solubility (µg/ml) Drug content (%) Solubility (µg/ml) 
0 44.4 42.43 87.08 53.52 
14 44.38 42.40 87.05 53.50 
21 44.35 42.38 87.02 53.47 
28 44.33 42.35 87.00 53.86 
43 44.30 42.33 86.98 53.44 
58 44.28 42.37 86.95 53.40 
73 44.34 42.31 86.97 53.38 
88 44.37 42.34 87.03 53.45 
 The co-crystals A5 and B 8 were subjected to FTIR spectroscopy, DSC and XPRD.  
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Table 7: Relevant bands in IR spectra of co-crystal A5, ibuprofen lysine, Co-former 
S. No. Functional groups Standard value (cm-1) Observed value (cm-1) Similar to 
Ibuprofen lysine PK 25 
1 O-H stretching  3600–3200 3452.92 3405 
2 C=O stretching 1730–1700 1625.7 1624 1669 
3 C-H stretching of the methyl group  3000–2850 2907.16 2921 
4 C-N stretching 1300–1000 1278.57 1291 
5 CH2 bending  1465 1449.24 1435 
6 C=C stretching aromatic ring  1600–1500 1628 1561 
7 O-H bending 920 913.129  
 
Table 8: Relevant bands in IR spectra of co-crystal B8, ibuprofen lysine, Co-former 
S. No. Functional groups Standard value (cm-1) Observed value (cm-1) Similar to Ibuprofen lysine PK 30 
1 O-H stretching  3600–3200 3456.78 3452.92 
2 C=O stretching 1730–1700  1626.66 1626.66 1624.73  
3 C-H stretching of methyl group  3000–2850  2925.48 2838.62 
4 C-N stretching 1300–1000  1224.58  1289.18 
5 CH2 bending  1465 1447.31  1432 
6 C=C stretching aromatic ring  1660–1600  1583.27 1561.09 1587.13 
7 O-H bending 920  914.093   
 
The resulting spectra of both the co-crystals were different from the IR 
spectra of ibuprofen lysine. The broad bands, in the region of 2500-3500 
cm, indicated hydrogen bond formation between ibuprofen and PK. The 
co-crystal spectrum was different from the ibuprofen spectrum in two 
specific regions: in between 900-1500 cm-1, characteristic of CH2 and CH3 
wags, and in between 820-850 cm-1 [19]. The co-crystals A5 and B8 
revealed numerous peaks in the region 900-1500 cm-1 confirming the 
presence of ibuprofen. The intensity of the peaks in between 820-850 
cm-1 was reduced in the co-crystal spectrum [19]. 
The co-crystals A5 and B8 revealed two characteristic bands, in the 
region 1730–1700 cm-1 for the C=O stretching and in the region of 
1660–1600 cm-1for the C=C stretching of the aromatic ring. It 
indicated the presence of ibuprofen in the solid phases of A5 and B8. 
However, the spectra of the co-crystals depicted changes in the 
frequency and bandwidth of interacting groups [18]. It was 
attributed to the blending of ibuprofen with PK and the subsequent 
changes in the oscillating dipoles. These peaks indicated the 
interaction between ibuprofen and PK and the formation of crystal 
lattice arrangement to some extent. It was predicted that the crystal 
lattice arrangement was not completely formed. The inability of 
completion of crystal lattice rearrangement was due to inadequate 
drug: co-former stoichiometric ratio. 
  
 
Fig. 2: Infra-red spectrum of ibuprofen lysine 
 
 
Fig. 3: IR spectrum of co-crystal A5 
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Fig. 4: IR spectrum of co-crystal B8 
 
It was inferred that the salt was not formed in between ibuprofen and 
the co-formers since the IR band due to C=O stretching was observed 
at 1624 cm-1and 1626 cm-1respectively. The IR spectra of the co-
crystals did not show a shift to lower wavenumbers in comparison 
with the API and the co-formers. It indicated the absence of a proton 
transfer from the co-former to ibuprofen lysine [18]. A strong band, in 
the range of 1610-1550 cm-1is observed in the IR spectra of aryl 
carboxylate salts and can be attributed to the asymmetric vibration. 
The IR spectrum did not reveal any band in this region. It was 
concluded that A5 and B8 was a co-crystal rather than a salt. 
Differential scanning calorimetry (DSC)  
The DSC curves of ibuprofen lysine and the co-formers are shown in 
fig. 5, 6 and 7. 
  
 
Fig. 5: DSC thermogram of ibuprofen lysine 
 
Ibuprofen lysine was subjected to thermal screening by DSC. (fig. 5) 
The DSC thermogram revealed a small endothermic peak at 72.35 ˚C, 
the sharp endothermic peak at 187.51 ˚C and a broad endotherm at 
231.5 ˚C. The first peak may be attributed to a small mass loss from 
the API sample. The mass loss was associated to vaporization of 
water from the API sample. The second sharp endotherm indicated a 
melting point of ibuprofen. The broad endotherm was attributed to 
the melting and decomposition of lysine. 
  
 
Fig. 6: DSC thermogram for PK-25 
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Fig. 7: DSC thermogram for PK-30, DSC thermo grams of the co-formers revealed typical polymeric behaviour. (fig. 6 and 7) 
 
 
Fig. 8: DSC thermogram of co-crystal A5 
 
 
Fig. 9: DSC thermogram of co-crystal B8 
 
The melting point of ibuprofen co-crystal was lower or different 
than the melting point of ibuprofen or the co-former [18]. However, 
the melting point of the co-crystal was similar to the melting point of 
ibuprofen lysine in our study. The DSC curves of the co-crystal A5 
and B8 (fig. 8 and 9 respectively) revealed an endothermic peak at 
187 ˚C and 184 ˚C respectively. It indicated the presence of 
ibuprofen lysine in the co-crystals. The endotherm, at 72.35 ˚C for 
ibuprofen lysine, was absent in the thermogram of the co-crystals. 
The melting point of nicotinamide-2-chloro-4-nitrobenzoic acid c0-
crystal was higher than the individual components [8]. The higher 
melting point indicated higher stability of the co-crystal. The DSC 
curve of A5 (fig. 8) revealed an intense endothermic peak with a 
small shoulder at 233 ˚C. The DSC curve of B8 (fig. 9) revealed a 
broad endotherm at 233 ˚C. These peaks were different in 
appearance from that of ibuprofen lysine. These peaks indicated the 
formation of H bonds and the possibility of crystal lattice 
arrangement between ibuprofen lysine and the co-formers to some 
extent. It was predicted that the crystal lattice arrangement was not 
completely formed. The inability of completion of crystal lattice 
rearrangement was due to inadequate drug: co-former 
stoichiometric ratio.  
PXRD study  
The formation of co-crystals was confirmed from PXRD study since 
the diffraction lines of the co-crystals A5 and B8 were considerably 
different from the peak positions of ibuprofen lysine and the co-
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former. Ibuprofen lysine displayed the prominent peaks at 2˚θ=10.5, 
11.19, 12.17, 12.95, 15.30, 16.60. 18.91. (fig. 10) Our results are 
corroborated by Renato et al., who have reported the characteristic 
peaks of ibuprofen at 2˚θ=12.24, 16.3 [19]. 
  
 




Fig. 11: PXRD patterns of PK-25 
 
 
Fig. 12: PXRD patterns of PK-30 
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Renato et al. observed the difference between the XRD patterns of 
ibuprofen-nicotinamide co-crystals and ibuprofen/nicotinamide. The 
diffraction lines of the co-crystals A5 and B8 were considerably different 
from the peak positions of ibuprofen and the co-former [19]. (fig. 13 and 
14) A prominent peak, at 2˚θ= 10.86 and 10.58, along with the 
appearance of numerous peaks, confirmed the formation of new 
crystalline structure. The peaks indicated the crystal lattice arrangement 
between ibuprofen and the co-formers to some extent. The inability of 
completion of crystal lattice rearrangement was due to inadequate drug: 
co-former stoichiometric ratio. 
 
 
Fig. 13: PXRD patterns of co-crystal A5 
 
 
Fig. 14: PXRD patterns co-crystal B8 
 
Morphology study  
Morphologies of ibuprofen lysine drug substance, the co-
formers, and the co-crystal particles were investigated. 
Ibuprofen lysine crystals appeared as irregular crystals 
agglomerated in bundles (fig. 15), whereas the co-formers 
appeared as transparent, almost rectangular particles. (fig. 16 
and 17) Microscopic analysis of solids A5 and B8 were 
consistent with DSC and FTIR study. The characteristic 
appearance of ibuprofen lysine and Polyvinylpyrrolidone 
disappeared in B8 solid. It appeared as irregular solid 
aggregates making it impossible to differentiate between co-
crystal components. (fig. 18) The solid A5 was rectangular, 
transparent, and opaque (fig. 19). 
 
Fig. 15: ibuprofen lysine 
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Fig. 16: PK 25 
 
/  
Fig. 17: PK 30 
 
Fig. 18: Co-crystal B8 
 
 
Fig. 19: Co-crystal A5 
 
Evaluation of tablet formulations of co-crystals of ibuprofen 
lysine  
The tablets were round, white, smooth in appearance. Tablets T1, 
T2, T3 complied with tablet thickness, diameter, weight variation, 
hardness, friability (table 9) 
 
Table 9: Characterization of tablet formulations 
S. No. Parameter T1 tablets T2 tablets T3 tablets 
1 Average weight (g) 0.3269±0.014 0.3107±0.009 0.3418±0.006 
2 Hardness (kg/cm2) 4.5±0.018 4.6±0.012 4.6±0.015 
3 Disintegration time (min) 11.7  9.89  17.85  
4 Friability (% weight/weight) 1.1 0.6 0.61 
5 Dimension Thickness (mm) 0.4833±0.0057 0.4766±0.0057 0.4833±0.0057 
Diameter (mm) 0.8733±0.0057 0.08833±0.0057 0.088±0.01 
 Each observation is an average of three experiments (n=3)±SD 
 
The results revealed that the dissolution rate of T2 tablets (co-
crystal A5) was lower than the dissolution rate of T1 tablets (IL 
alone). (table 10) It was attributed to the method of preparation of 
the co-crystals. The co-crystal A5 was prepared by LAG in two steps 
1) addition of solvent to the API: co-former mixture and 2) 
mechanical shaking of the mixture. It is proposed that the co-former 
has formed the co-crystals. In addition, Polyvinylpyrrolidone, the co-
former, formed a viscous gel upon contact with water. This has 
promoted retardation of the drug release rate, as observed in T2 
tablets. SE method, employed for preparing the co-crystal B8, 
consists of 1) addition of solvent to the API: co-former mixture and 
2) evaporation of the solvent. The extent of interaction between IL 
and Polyvinylpyrrolidone, the co-former, was higher in SE method. 
Hence the co-former was unable to form the viscous gel. This has 
lead to higher dissolution rate of T3 tablets than the dissolution rate 
of T1 tablets (IL alone) (table 10). 
  
Table 10: In vitro drug release profile of T1, T2 and T3 tablets 
S. No. Time (min) % Drug release 
T1 tablets T2 tablets T3 tablets 
1 30 29.69±1.35 13.91±3.79 40.39±16.07 
2 60 55.90±0.97 29.52±6.49 96.14±13.98 
3 90 74.61±3.51 40.73±9.67 112.94±14.02 
4 120 77.35±3.77 47.90±3.14 113.57±13.89 
5 180 80.40±2.99 56.81±5.86 114.23±6.496 
6 240 81.93±4.89 60.38±6.19 -- 
7 300 77.34±2.19 59.28±4.62 -- 
8 360 76.48±6.07 59.24±3.07 -- 
 Each observation is an average of three experiments (n=3)±SD 
Kulkarni et al. 
Int J App Pharm, Vol 12, Issue 3, 2020, 22-32 
32 
In vivo study of tablet formulations of co-crystals of ibuprofen 
lysine  
The effect of ibuprofen formulations on reaction time in hot plate 
method are presented in table 11. The mean baseline observations 
were 2.043, 1.398, 1.668, 1.900 and 2.138 min respectively for 
Group I, II, III, IV and V with the corresponding coefficient of 
variation 19.69%, 12.31%, 8.85%, 5.45% and 25.13%. At 45 min of 
the study, the T2 tablet formulation increased the reaction time of 
heat sensation to 19.66% in Group I. At 15 and 45 min of study, the 
T3 tablet formulation increased the reaction time of heat sensation 
to 46.70 and 57.93%, respectively. At 15 and 45 min of study, the 
Brufen® tablet formulation increased the reaction time of heat 
sensation to 0.94 and 29.50%, respectively. At 60 and 120 min of 
study, the reaction time of heat sensation was higher for T2 and T3 
tablet formulations than T1 tablet formulation. 
 
Table 11: Analgesic activity of tablet formulations 
Time (min)  Reaction time (min) 
Group I Group II Group II Group IV Group V 
0 2.043±0.1969 1.398±0.1231 1.668±0.08845 1.900±0.05447 2.138±0.2513 
15 2.498±0.07319 2.623±0.1584 a***d*** e***f*** 2.403±0.2652 1.918±0.08645 c* d* e*** f*** 2.718±0.1726 
30 1.340±0.02614 e*f* 2.180±0.1526 a** c*** e*** f *** 2.660±0.1411 2.663±0.1855 a* b* e* f* 2.855±0.1753 
45 2.543±0.1299 3.323±0.06928 a*** b** c*** f* 3.010±0.3844 a* 2.695±0.1830 a** b* e* f* 2.663±0.1581 
60 3.328±0.8417 c** 3.698±0.1903 a*** b*** c*** 3.268±0.3166 a** 3.395±0.1696 a*** b*** c* d* 2.798±0.1993 
120 3.238±0.3677 c* 3.945±0.08703 a*** b*** c*** d* 3.160±0.4517 a* 3.350±0.2089 a*** b*** c* d* 2.065±0.1990 
 Where a = 0 min, b = 15 min, c = 30 min, d = 45 min, e = 60 min, f = 120 min, Each observation is an average of three experiments (n=6)±SEM 
 
The mean peak effect remained above 3 s between 60-120 min in 
group I, between 45-120 min in group II, between 45-60 min in 
group III, between 60-120 min in group IV and at 120 min in group 
V. The analgesic effect, in the increasing order, was demonstrated as 
Group II>Group IV and I>Group III>Group V. The co-crystal of 
ibuprofen lysine B8 demonstrated significant analgesic activity.  
CONCLUSION 
The formation of the co-crystals in between ibuprofen lysine (IL) and 
polyvinylpyrrolidone K-25 (PK 25)/polyvinylpyrrolidone K-30 (PK 30) 
was confirmed. It indicated an improvement in aqueous solubility of IL 
by co-crystallization of IL with PK 25 and PK 30. It demonstrated that a 
tablet of co-crystal with sufficient hardness, necessary for manufacturing 
and distribution, can be formulated. The co-crystals of ibuprofen lysine 
demonstrated significant analgesic activity than the marketed tablet. The 
present study illustrates the utility of PK 25 and PK 30 as safe and 
promising co-crystal formers. 
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